Dequalinium Chloride
CAS 522-51-0
Dequalinium Chloride (CAS 522-51-0) is a Phase 4 pharmaceutical compound with 7 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 2100.558666666667 nM | 60 | - |
| - | Potency | 32753.7 nM | 50 | - |
| - | IC50 | 3649.01946875 nM | 25 | - |
| - | EC50 | 743.275 nM | 4 | - |
| - | Ki | 194 nM | 3 | - |
| - | MIC | 8250 nM | 2 | - |
| - | Kd | 180 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Dequalinium Chloride used for in pharmaceutical contexts?
Dequalinium Chloride (CAS 522-51-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Dequalinium Chloride?
No adverse-event association or SIDER side-effect rows are rendered for Dequalinium Chloride in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Dequalinium Chloride also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Dequalinium Chloride with EU status "permitted".
What clinical phase is Dequalinium Chloride in?
Dequalinium Chloride is rendered with ChEMBL max phase 4 (approved).